arrow
H

Hirokazu Tanaka

kindai university
H指数:28
被引数:2,551

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum

从关西骨髓瘤论坛对极高龄多发性骨髓瘤治疗的见解

2025-12-310
PRE
Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells

抗精神病药物Chlorpromazine抑制STAT5信号通路,克服由门控突变FLT3-ITD/F691L介导的耐药性,并与Quizartinib在FLT3-ITD阳性细胞中协同作用

2025-09-300
OAAI
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
2024-08-210
PRE
PERIPHERAL BLOOD IMMUNOPHENOTYPE OF PATIENTS WITH SLE IN MAINTENANCE PHASE WHO WERE ABLE TO DISCONTINUE GLUCOCORTICOIDS AFTER INTERVENTION WITH BELIMUMAB: LOOPS REGISTRY, FLOW STUDY

接受贝利木单抗干预后能够停用糖皮质激素的SLE维持期患者的 peripheral blood immunophenotype:LOOPS登记研究,FLOW研究

2024-06-010
PRE
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

daratumumab后elotuzumab治疗多发性骨髓瘤的疗效恶化: 一项多中心回顾性研究

2024-03-161
PRE
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
2023-03-295
OAAI
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
2022-12-132
OAAI
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

卡非佐米-来那度胺-地塞米松和卡非佐米-地塞米松在复发/难治性多发性骨髓瘤中的真实世界有效性和安全性分析: 多中心回顾性分析

2022-06-248
OAAI
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma
2021-03-281
PRE